UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2211-6
Program Prior Authorization/Medical Necessity
Medication Berinert® (C1 esterase inhibitor [human])
P&T Approval Date 6/2020, 4/2021, 4/2022, 4/2023, 4/2024, 4/2025
Effective Date 7/1/2025
1. Background:
Berinert is a plasma-derived C1 esterase inhibitor (human) indicated for the treatment of acute
abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric
patients. The safety and efficacy of Berinert for prophylactic therapy have not been established.1
2. Coverage Criteria a:
A. Initial Authorization
1. Berinert will be approved based on all of the following criteria:
a. Diagnosis of hereditary angioedema (HAE) as confirmed by one of the following:
(1) C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented
by one of the following (per laboratory standard):
(a) C1-INH antigenic level below the lower limit of normal
(b) C1-INH functional level below the lower limit of normal
-OR-
(2) HAE with normal C1 inhibitor levels and one of the following:
(a) Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-1,
plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-
sulfotransferase 6
(b) Recurring angioedema attacks that are refractory to high-dose antihistamines
with confirmed family history of angioedema
(c) Recurring angioedema attacks that are refractory to high-dose antihistamines
with unknown background de-novo mutation(s) (i.e., no family history) (HAE-
unknown)
-AND-
b. Both of the following:
(1) Prescribed for the acute treatment of HAE attacks
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Not used in combination with other products indicated for the acute treatment of
HAE attacks (e.g., Firazyr, Ruconest)
-AND-
c. Submission of medical records documenting a history of failure, contraindication, or
intolerance to Ruconest (C1 esterase inhibitor [recombinant])
-AND-
d. Prescribed by one of the following:
(1) Immunologist
(2) Allergist
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Berinert will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Berinert therapy
-AND-
b. Both of the following:
(1) Prescribed for the acute treatment of HAE attacks
-AND-
(2) Not used in combination with other products indicated for the acute treatment of
HAE attacks (e.g., Firazyr, Ruconest)
-AND-
c. Prescribed by one of the following:
(1) Immunologist
(2) Allergist
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; September 2021.
2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the
management of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Jan 10.
3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed),
UpToDate, Waltham, MA, 2024.
4. Busse, P., Christiansen, S., Riedl, M., et. al. “US HAEA Medical Advisory Board 2020
Guidelines for the Management of Hereditary Angioedema.” The Journal of Allergy and Clinical
Immunology. 2020 September 05.
5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the
management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-
1990. doi:10.1111/all.15214
Program Prior Authorization/Medical Necessity - Berinert (C1 esterase inhibitor
[human])
Change Control
6/2020 New program.
4/2021 Added diagnosis criteria. Updated references.
4/2022 Updated background to include the safety and efficacy for prophylactic
use has not been established. Updated references.
4/2023 Annual review. Updated references.
4/2024 Annual review with update to examples of genetic variant(s) and
diagnostic criteria with normal C1 inhibitor levels. Updated language
for reauthorization criteria.
4/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
3